Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers

Mashael Algethami(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Chandar Jaipal(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Adel Alblihy(University of Nottingham), Juliette Brownlie(University of Nottingham), Katia A. Mesquita(University of Nottingham), Ahmed Shoqafi(University of Nottingham), Jennie Jeyapalan(University of Nottingham), Nigel P. Mongan(University of Nottingham), Corinne L. Woodcock(University of Nottingham), Andrew R. Green(Nottingham Biomedical Research Centre), Michael S. Toss(Nottingham City Hospital)
npj Breast Cancer
March 30, 2023
10.1038/s41523-023-00524-3
Cited by 14

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374